Reprint

Update on X-linked Hypophosphatemia

Edited by
January 2024
146 pages
  • ISBN978-3-0365-9686-0 (Hardback)
  • ISBN978-3-0365-9687-7 (PDF)

This is a Reprint of the Special Issue Update on X-linked Hypophosphatemia that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

Rickets and osteomalacia are associated with impaired mineralization in growth plate cartilage and the bone osteoid. Vitamin D deficiency has been one of the major causes for rickets and osteomalacia. In addition, it has been also known that there are diseases called vitamin D-resistant rickets/osteomalacia which cannot be cured by native vitamin D. Since the cloning of FGF23 in 2000, it has become clear that most cases of vitamin D-resistant rickets/osteomalacia are caused by excessive actions of FGF23. X-linked hypophosphatemia (XLH) is the most common cause of inherited FGF23-reltated hypophosphatemic rickets. Patients with XLH suffer from life-long morbidity of bone, cartilage, ligament, joint, tooth and muscle which significantly affects quality of life. Since FGF23 was shown to be the humoral factor causing hypophosphatemia in patients with XLH, anti-FGF23 antibody that blocks the actions of FGF23 has been developed and become clinically available in several countries. The introduction of this new drug together with advanced knowledge concerning physiological and pathophysiological significance of FGF23 has further stimulated research and promoted dissemination of fruits of the studies in this field. From these backgrounds, a variety of both basic and clinical topics concerning XLH are covered in this special issue to provide up-to-date summaries of the current understanding.

Related Books

May 2022

Bone Development and Disease in Infants

Medicine & Pharmacology
December 2020

Vitamin D in 2020

Public Health & Healthcare
April 2023

COVID-19 and Other Pleiotropic Actions of Vitamin D

Biology & Life Sciences
...
February 2019

Vitamin D and Human Health

Biology & Life Sciences
February 2023

Osteoporosis and Related Bone Metabolic Disease

Medicine & Pharmacology

The recommendations have been generated using an AI system.